Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 7/20 | 0.33 |
| ▸ | NPC1 | O15118 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18644689 | 0.79 | ALDH1A1 (0.40) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL569821 | 0.79 | NOS1 (0.41) | MAPTALDH1A1MEN1KMT2ANOS1 | |
| SCHEMBL18644693 | 0.75 | ALDH1A1 (0.40) | MAPTALDH1A1MEN1KMT2AGSK3B | |
| SCHEMBL11833656 | 0.74 | ALDH1A1 (0.42) | MAPTALDH1A1MEN1KMT2ANOS1 | |
| SCHEMBL11229318 | 0.72 | NOS1 (0.39) | MAPTALDH1A1MEN1KMT2ANOS1 | |
| SCHEMBL2677906 | 0.72 | NOS1 (0.44) | MAPTALDH1A1MEN1KMT2ANOS1 | |
| SCHEMBL14844522 | 0.72 | ALDH1A1 (0.50) | MAPTALDH1A1MEN1KMT2ANOS1 | |
| SCHEMBL12179254 | 0.71 | ALDH1A1 (0.46) | MAPTALDH1A1MEN1KMT2ANOS1 | |
| SCHEMBL1503950 | 0.71 | ALDH1A1 (0.45) | MAPTALDH1A1NPC1SMN1; SMN2GAA | |
| SCHEMBL6114286 | 0.71 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | MAPT 964/4885ALDH1A1 204/4885MEN1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.